How did INVX's revenue and expenses shift in Q4 2024 compared to previous quarters?

Innovex Pharmaceuticals (INVX) exhibited significant improvements in both revenue and net income in Q4 2024 compared to the previous quarter, Q3 2024:

1. **Revenue Shift**:
- **Q4 2024**: INVX reported a total revenue of $250.69 million for Q4 2024.
- **Q3 2024**: The revenue for Q3 2024 was $151.82 million.
- **Comparison**: The revenue increased by approximately $98.87 million, indicating a substantial growth in this period.

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|INVX|INVX.N|Innovex|2023 Q4|-34.042479436248655|1.3319E8|169|
|INVX|INVX.N|Innovex|2024 Q1|40.865019534474214|1.27997E8|169|
|INVX|INVX.N|Innovex|2024 Q2|34.2997756871673|1.20342E8|169|
|INVX|INVX.N|Innovex|2024 Q3|9.153329594639288|1.51817E8|169|

2. **Net Income Shift**:
- **Q4 2024**: The net income for Q4 2024 was $31.79 million.
- **Q3 2024**: Net income in Q3 2024 was $82.59 million.
- **Comparison**: While there was a decrease in net income from $82.59 million in Q3 2024 to $31.79 million in Q4 2024, it is important to note that Q3 2024 had an unusually high net income compared to other quarters, making the decrease less significant in the context of previous quarters' performance.

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|INVX|INVX.N|Innovex|2023 Q4|-71.3971192458564|1.8448E7|169|
|INVX|INVX.N|Innovex|2024 Q1|610.3851146689744|1.6417E7|169|
|INVX|INVX.N|Innovex|2024 Q2|-152.0241171403962|-1812000|169|
|INVX|INVX.N|Innovex|2024 Q3|437.4593257841989|8.2586E7|169|

Overall, INVX showed a strong performance in terms of revenue in Q4 2024, despite a slight dip in net income compared to the previous quarter.